TCI GENE Return on Equity

TCI GENE (6879.TWO) currently reports a ROE of 9.28%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore TCI GENE's ROE history and peer comparisons.

TCI GENE's ROE of 9.28% is higher than the Healthcare sector average of -100.59%. That is roughly 109.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but TCI GENE's current 9.28% should be judged against Healthcare norms (sector average: -100.59%) and against 6879.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 9.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for TCI GENE, and consider following 6879.TWO for alerts when major investors trade the stock.

TCI GENE is classified in the Healthcare sector. On ROE, it currently shows 9.28% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6879.TWO with unrelated industries.